Pipeline

Drug Discovery Programs

Arontier's active joint R&D and proprietary drug discovery programs spanning small molecules, protein design, and peptide design.

5+
Proprietary
9+
Total Programs
10+
Disease Areas
8+
Modalities
Small Molecule
AR-2101 Proprietary Small Molecule

CAF

Hit to Lead
Lead Optimization
Non-clinical
IND

Current stage: Non-clinical

AR-2114 Proprietary Small Molecule

CAF

Hit to Lead
Lead Optimization
Non-clinical
IND

Current stage: Lead Optimization

AR-2302 Collaboration Small Molecule

Diabetes/Obesity

Hit to Lead
Lead Optimization
Non-clinical
IND

Current stage: Non-clinical

AR-2304 Collaboration Small Molecule

NASH

Hit to Lead
Lead Optimization
Non-clinical
IND

Current stage: Lead Optimization

AR-2307 Collaboration Small Molecule

Oncology

Hit to Lead
Lead Optimization
Non-clinical
IND

Current stage: Lead Optimization

TPD
AR-2313 Collaboration TPD

CAF

Hit to Lead
Lead Optimization
Non-clinical
IND

Current stage: Hit to Lead

Biologics
AR-6312 Collaboration Biologics

Vaccine (RSV)

Hit to Lead
Lead Optimization
Non-clinical
IND

Current stage: Non-clinical

AR-6308 Collaboration Biologics

Delivery (Ferritin-like)

Hit to Lead
Lead Optimization
Non-clinical
IND

Current stage: Lead Optimization

AR-6316 Collaboration Biologics

Undisclosed

Hit to Lead
Lead Optimization
Non-clinical
IND

Current stage: Lead Optimization

Interested in co-development?

We are open to collaborative drug development programs across our pipeline. Let us know your therapeutic area of interest.

Contact Us Our Technology